ArticleWorld journal of urology2021
Water vapor therapy (Rezūm) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study.
Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.World journal of urology · 2025Pooled it
- Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH.Prostate cancer and prostatic diseases · 2025Pooled it
- Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: An Umbrella Review and Updated Meta-Analysis.The world journal of men's health · 2026Article
- The double-decker technique for transurethral water vapor therapy (Rezūm) in catheter-dependent patients: A step-by-step guide and results from a prospective registry.Investigative and clinical urology · 2026Article
- The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Review
- Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients.Prostate cancer and prostatic diseases · 2026Article
- The dark side of transurethral access for LUTS/BPH surgery: a narrative review.Asian journal of andrology · 2026Review
- Patients with frailty, benign prostatic hyperplasia and indwelling bladder catheter: What are the 1-year outcomes after Rezūm therapy?Current urology · 2025Article
- Expert consensus on Rezūm™: Indications, surgical technique and postoperative care.BJUI compass · 2025Review
- Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?Asian journal of andrology · 2024Review
- Water Vapor Therapy and Zonal Anatomy of the Prostate.International neurourology journal · 2024Article
- Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate.Prostate cancer and prostatic diseases · 2024Article
- Is water vapor thermal therapy safe and feasible in elderly and frail men? The Italian experience.World journal of urology · 2024Article
- Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study.Prostate cancer and prostatic diseases · 2023Article
- Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: efficacy and safety analysis of a real-world cohort of 211 patients.World journal of urology · 2023Observational
- Office-Based Procedures for BPH.Current urology reports · 2021Review
- New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes.European urology open science · 2021Review
- Role of Rezum in the treatment of benign prostate hyperplasia: A review of the literature.Turkish journal of urology · 2021Article
- Emerging Data on the Safety and Efficacy of Transurethral Water Vapour Therapy for Benign Prostatic Hyperplasia.Research and reports in urology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRezūm is the latest developed minimally invasive treatment for benign prostatic hyperplasia (BPH). We aimed to carefully assess the functional outcomes of patients treated with Rezūm for BPH.
methodsWe prospectively followed 135 consecutive patients treated by Rezūm at 5 institutions from June 2019 to August 2020. The International Prostate Symptom Score (IPSS), International Consultation on Incontinence Questionnaire-Short Form (ICIQ-UI SF), the Overactive Bladder Questionnaire-Short Form (OAB-q SF) score, the International Index of Erectile Function (IIEF-5) and questions 9 and 10 to assess ejaculatory dysfunction were recorded. Election criteria were age > 18, no prior prostate interventions, IPSS ≥ 13, post-void residual ≤ 250 mL, prostate volume between 30 and 120 cc.
resultsThe median operative time was 10.5 (IQR 8.7-15) min. All patients were dismissed few hours after surgery with indwelling urinary catheter that was removed after a median of 7 (IQR 7-10) days. A significantly decrease of IPSS from baseline at first (p = 0.001) and third (p < 0.0001) month after surgery was reported. No difference was reported in terms of ICIQ-UI SF score postoperatively. A mild reduction of the OAB-q SF score was reported at 1 month from surgery (p = 0.06) that turned significant at 3 months postoperatively (p < 0.0001). A slight but statistically significant increase of the IIEF-5 score was reported from baseline at 6 months (p = 0.04). Postoperatively, patients reported a significantly decrease of ejaculatory dysfunction after alpha-blocker interruption.
conclusionRezūm treatment is a feasible minimally invasive option for patients with BPH symptoms and showed optimal early functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.